Orthofix International NV (NASDAQ:OFIX) CEO Brad Mason sold 9,538 shares of the stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $36.83, for a total transaction of $351,284.54. Following the transaction, the chief executive officer now owns 151,219 shares of the company’s stock, valued at approximately $5,569,395.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Orthofix International NV (NASDAQ:OFIX) opened at 37.03 on Monday. The stock has a market capitalization of $660.10 million, a P/E ratio of 70.80 and a beta of 0.45. The stock has a 50 day moving average of $39.46 and a 200-day moving average of $43.15. Orthofix International NV has a one year low of $35.61 and a one year high of $48.25.

Orthofix International NV (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, October 31st. The medical device company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.02. The firm earned $98.50 million during the quarter, compared to analyst estimates of $103.40 million. Orthofix International NV had a return on equity of 9.01% and a net margin of 2.41%. Orthofix International NV’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 EPS. Equities analysts forecast that Orthofix International NV will post $1.43 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of OFIX. GSA Capital Partners LLP raised its position in shares of Orthofix International NV by 66.2% in the second quarter. GSA Capital Partners LLP now owns 82,612 shares of the medical device company’s stock worth $3,503,000 after buying an additional 32,920 shares during the period. EAM Investors LLC acquired a new position in shares of Orthofix International NV during the second quarter worth $1,272,000. Gabelli Funds LLC raised its position in shares of Orthofix International NV by 0.3% in the second quarter. Gabelli Funds LLC now owns 290,450 shares of the medical device company’s stock worth $12,315,000 after buying an additional 1,000 shares during the period. DIAM Co. Ltd. raised its position in shares of Orthofix International NV by 19.3% in the second quarter. DIAM Co. Ltd. now owns 26,065 shares of the medical device company’s stock worth $1,105,000 after buying an additional 4,214 shares during the period. Finally, Emerald Acquisition Ltd. acquired a new position in shares of Orthofix International NV during the second quarter worth $4,435,000. 93.03% of the stock is owned by institutional investors and hedge funds.

OFIX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Orthofix International NV from a “hold” rating to a “strong-buy” rating and set a $49.00 price target on the stock in a report on Thursday, August 4th. TheStreet downgraded shares of Orthofix International NV from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd.

Orthofix International NV Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

5 Day Chart for NASDAQ:OFIX

Receive News & Stock Ratings for Orthofix International NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International NV and related stocks with our FREE daily email newsletter.